ELI LILLY AND COMPANY LTD
- Country
- United Kingdom
- Type
- Beneficiary
- Website
- www.lilly.com
- Grants received
- 42
Funding record
- 42 grants on record
- €1,853,319.57 awarded in total
- 2014–2025 span of the record
Grants recorded here are the ones our sources publish, and the total is the sum of those. It is not a statement of this organisation's total funding.
Programmes
37 further grants are on record without a programme named by the source, or under a programme outside the largest shown here.
Frequent partners
Organisations this one has been funded alongside on two or more projects. A single shared consortium is not counted: the largest here has 195 members, and being on one list together is not a collaboration.
- JANSSEN PHARMACEUTICA NV
- NOVARTIS PHARMA AG
- ASTRAZENECA AB
- BAYER AKTIENGESELLSCHAFT
- GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LIMITED
- NOVO NORDISK A/S
- SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT
- THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
Calls from this organisation
No published calls from this organisation.
Grants received
- Research in Europe and Diversity Inclusion
- Propelling the shift toward the future of circular, safe and sustainable packaging and single use device ecoDesigned solutions through healthcare environments
- Gravitate–Health: Empowering and Equipping Europeans with health information for Active Personal Health Management and Adherence to Treatment
- H2O Health Outcomes Observatory
- Prioritisation and Risk Evaluation of Medicines in the EnviRonment
- Stratification of Obesity Phenotypes to Optimize Future Therapy
- Translational approaches to disease modifying therapy of type 1 diabetes - HARVESTing the fruits of INNODIA
- Better control and treatment of immune-mediated diseases by exploring the universe of microenvironment imposed tissue signatures and their correlates in liquid biopsies
- Identifying Digital Endpoints to Assess FAtigue, Sleep and acTivities in daily living in Neurodegenerative disorders and Immune-mediated inflammatory diseases
- Building an ecosystem for better monitoring and communicating of medication safety in pregnancy and breastfeeding: validated and regulatory endorsed workflows for fast, optimised evidence generation
- CARdiomyopathy in type 2 DIAbetes mellitus
- Efficiently Networking European Neurodegeneration Research
- EBiSC2 – A sustainable European Bank for induced pluripotent Stem Cells
- Integrated IMMUnoprofiling of large adaptive CANcer patients cohorts
- Translational Safety Biomarker Pipeline (TransBioLine): Enabling development and implementation of novel safety biomarkers in clinical trials and diagnosis of disease
Data source
© European Union, 2026. Source: CORDIS. Reused under Commission Decision 2011/833/EU — CC BY 4.0.
Retrieved from the source on .
Personal data of natural persons has been dissociated by quiescence.eu.
This service is not affiliated with, sponsored or endorsed by the data publishers.